BYD Company Limited
002594
Orient Group Incorporation
600811
Hanshow Technology
301275
4
Kweichow Moutai
600519
5
Contemporary Amperex Technology
300750
CN Stock MarketDetailed Quotes
300109 Boai NKY Medical
- 16.01
- -0.24-1.48%
Market Closed Mar 4 15:00 CST
7.76BMarket Cap19.43P/E (TTM)
16.22High15.75Low174.50KlotVolume16.22Open16.25Pre Close278.41MTurnover3.89%Turnover Ratio15.74P/E (Static)484.70MShares18.9852wk High2.21P/B7.18BFloat Cap9.7652wk Low19.50Limit Up448.34MShs Float59.97Historical High13.00Limit Down2.89%Amplitude1.44Historical Low0.67Dividend TTM15.95Avg Price92.01KlotAsk4.17%Div YieldTTM100Lot Size77.57KlotBid
Boai NKY Medical News
Earnings Growth Outpaced the Favorable 15% CAGR Delivered to Boai NKY Medical Holdings (SZSE:300109) Shareholders Over the Last Three Years
Alibaba Earnings Reports: AI drives cloud Business back to double-digit growth with over 0.09 million derivative models.
On February 20, Alibaba Group announced its third-quarter results for the fiscal year 2025 (natural year October-December 2024), showing an accelerated growth trend in Alibaba's core Business under the "AI-driven" Global Strategy. In this quarter, Alibaba Cloud's AI-related product revenue achieved triple-digit year-on-year growth for six consecutive quarters, helping Alibaba Cloud's revenue return to double-digit growth at 13%. The AI-driven marketing tool "Full Site Promotion" saw a steady increase in merchant penetration. Recently, Alibaba's brand new open-source flagship model Qwen2.5-Max gained significant attention, achieving globally leading results in multiple authoritative benchmark tests.
Alibaba's Q3 Earnings Reports: Cloud and e-commerce accelerated growth, with AI revenue showing triple-digit growth for six consecutive quarters.
On February 20, Alibaba Group released the performance for the third quarter of fiscal year 2025, highlighting that the focus on Global Strategy over the past year has yielded continuous results, with core Business accelerating growth. In this quarter, e-commerce Business grew rapidly, Alibaba Cloud's commercial revenue returned to double-digit growth, and revenue from AI-related products maintained triple-digit growth for six consecutive quarters. Standing at the starting point of a new technological cycle, AI is expected to become Alibaba's new growth engine for the future. 'This quarter's performance fully demonstrates our significant progress in the strategy of 'User First, AI Driven', with core Business growth accelerating once again. In this quarter, the customer management revenue of Taotian Group grew by 9%, with
Boai NKY Medical (300109.SZ): It is expected that this year there will still be a certain increase in Order and shipment volume in the New energy Fund.
On February 17, Gelonghui reported that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company expects a certain increase in orders and shipments in the New energy Fund this year.
Is Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Latest interview with "Wooden Sister": DeepSeek exacerbates the collapse of AI costs, which is a good thing.
Kathy Wood, the founder and CEO of Ark Investment Management, stated that the emergence of DeepSeek in China has intensified competition in the AI field, which is a positive development that will help Technology companies cut costs and improve their platforms. DeepSeek's newly open-sourced AI model is widely seen as a challenge to the USA's dominance in the Technology Industry, resulting in a 3% drop in the NASDAQ 100 Index, the largest single-day decline since December last year. Wood said that now is not the time for stricter regulation of Technology because DeepSeek has intensified the competition in AI.
Boai NKY Medical (300109.SZ) Director Zhao Wei received a notice of case filing.
Boai NKY Medical (300109.SZ) announced that Director Zhao Wei recently received a "Notice from the China Securities Regulatory Commission..."
Returns On Capital Are Showing Encouraging Signs At Boai NKY Medical Holdings (SZSE:300109)
Is Boai NKY Medical Holdings (SZSE:300109) Using Too Much Debt?
Boai NKY Medical (300109.SZ): The construction project for the annual production of 0.012 million tons of the new PVP polymerization unit has been initiated.
On December 23, Gelonghui reported that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company's PVP annual production capacity is 0.02 million tons. To expedite the digestion of the old and new NVP monomer production lines totaling 0.035 million tons, the company has initiated a construction project for a new PVP polymerization unit with an annual output of 0.012 million tons. A certain increase is expected in the New energy Fund industry in 2025.
Boai NKY Medical (300109.SZ): Currently, there are no PEEK products.
Gelonghui reported on December 23 that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company currently does not have PEEK products.
Boai NKY Medical (300109.SZ): Related Shareholders have terminated their joint action agreement and changed the actual controller.
On December 16, Glonghui reported that Boai NKY Medical (300109.SZ) announced that it recently received a notice from the company's controlling shareholder and one of the actual controllers, Mr. Ren Dalong. He, along with Mr. Wang Donghu, Mr. Yang Haijiang, Mr. Zhang Junzheng, and Mr. Yang Hongbo, decided through amicable consultation to terminate the "Joint Action Agreement" signed with Wang Donghu and Yang Haijiang on December 20, 2023. The period of joint action will be from December 21, 2023, to December 20, 2024. At the same time, they will also terminate the "Joint Action Agreement" signed with Wang Donghu, Yang Haijiang, Zhang Junzheng, and Yang Hongbo on February 18, 2024.
The Market Lifts Boai NKY Medical Holdings Ltd. (SZSE:300109) Shares 28% But It Can Do More
Boai Nky Medical (300109.SZ): The company currently has an aggregate capacity of 0.034 million tons of nvp and 0.02 million tons of pvp.
On November 28, Gelonghui reported that boai nky medical (300109.SZ) indicated on the investor interaction platform that the company currently has an aggregate capacity of 0.034 million tons of NVP and 0.02 million tons of PVP. In the future, based on market sales and the expansion of product applications, the company will timely adjust the NVP monomer capacity and PVP aggregation capabilities.
Boai nky medical (300109.SZ): The company's products can be used in solid state batteries.
According to Boai Nky Medical (300109.SZ) on the investor interaction platform, the company's products can be used in solid state batteries.
Boai NKY Medical Holdings' (SZSE:300109) Shareholders Have More To Worry About Than Only Soft Earnings
New Open Source: 2024 Q3 Report
Boai Nky Medical (300109.SZ) released its performance for the first three quarters, with a net income of 0.311 billion yuan, a year-on-year decrease of 23.13%.
Boai nky medical (300109.SZ) disclosed the third quarter report of 2024, with the company achieving revenue of 11....
Boai Nky Medical (300109.SZ): The net income in the third quarter was 98.3134 million yuan, a 31.11% year-on-year decrease.
On October 22, Geelong released its third quarter report for 2024. In the third quarter of 2024, the company achieved revenue of 0.376 billion yuan, a decrease of 12.00% year-on-year; net income attributable to the company's shareholders was 98.3134 million yuan, a decrease of 31.11% year-on-year; net income after excluding non-recurring gains and losses was 0.104 billion yuan, a decrease of 27.73% year-on-year; basic earnings per share were 0.20 yuan per share.
Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's On An Uptrend: Are Strong Financials Guiding The Market?